2019 Volume 25
Objective: To investigate the occurrence of BRAFV600E and RAS mutations in thyroid papillary
carcinoma (PTC) and to study their correlation with clinicopathological features of PTC.
Methods Relevant information of PTC was downloaded and organized from The Cancer
Genome Atlas (TCGA) via cBioPortal, then the gene mutation and clinical information of
402 PTC samples were analyzed. The correlation of BRAFV600E and RAS mutations with
clinicopathological features and prognosis of PTC were subjected to univariate analysis.
Secondly, we use Binary Logistic multivariate analysis to analyze the factors screened above.
Results BRAFV600E mutation rate is 48.5% (195/402) and RAS mutation rate is 10.2% (41/402)
in 402 cases of PTC. Univariate analysis showed that BRAFV600E mutation has nothing to do
with age and sex of the patient. There is a significant correlation among BRAFV600E mutation
and lymph node metastasis, extrathyroidal invasion, staging, recurrence, progression and
pathological subtypes in PTC. There is no significant correlation among RAS and age, sex,
staging, recurrence, progression. There is a significant correlation among RAS and lymph node
metastasis, extrathyroidal invasion and pathological subtypes in PTC. Multivariate logistic
regression analysis indicated that there is a significant correlation among BRAFV600E mutation
and extrathyroidal invasion, pathological subtypes in PTC. There is a significant correlation
among RAS and lymph node metastasis, extrathyroidal invasion and pathological subtypes in
PTC. Conclusion The mutation rate of BRAFV600E was significantly higher than that of RAS in
PTC. Mutations in BRAFV600E and RAS can be used as predictors of prognosis in PTC.
Archived Files and Locations
|application/pdf 251.1 kB ||
access all versions, variants, and formats of this works (eg, pre-prints)